Summary & Overview
HCPCS C9809: Cryoablation Needle for Post-Surgical Pain Relief
HCPCS Level II code C9809 identifies a cryoablation needle and associated disposable components for non-opioid post-surgical pain relief, reflecting a growing policy emphasis on alternative analgesic strategies. The code captures supply of qualifying cryoablation systems (for example, the iovera system) designated under the CAA, 2023, and is relevant to facility billing and device procurement nationally. It matters because it creates a codified pathway for reporting and potentially reimbursing device-based, non-opioid approaches to acute post-operative pain management.
Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of the clinical context for device-based cryoablation for post-surgical pain, typical sites of service where the device is used, and the implications for billing workflows. The publication summarizes available national-level benchmarks where present, highlights relevant policy updates tied to section 4135 of the CAA, 2023, and outlines practical coding considerations for claims and invoicing workflows. Data not available in the input is noted where applicable.
Billing Code Overview
HCPCS Level II code C9809 describes a cryoablation needle system, including the needle/tip and all disposable system components, identified as a non-opioid medical device for post-surgical pain relief under section 4135 of the CAA, 2023. The device example cited is the iovera system.
Service Type: Device supply for targeted cryoablation therapy for post-surgical pain relief
Typical Site of Service: Outpatient clinic, ambulatory surgical center, or hospital outpatient department
Clinical & Coding Specifications
Clinical Context
A typical patient is a 55-year-old ambulatory adult who underwent outpatient knee arthroplasty and reports persistent localized postoperative focal nociceptive pain at the surgical incision and periarticular soft tissues despite multimodal systemic analgesia. The orthopedist or interventional pain specialist identifies a concentrated region of superficial sensory innervation amenable to percutaneous cryoneuroablation using a cryoablation needle system (e.g., iovera). After informed consent and verification of Medicare/non-opioid device qualification, the patient is positioned in a procedure suite or ambulatory surgical center. Local anesthesia is administered, ultrasound or landmark guidance is used to place the cryoneuroablation needle/tip adjacent to the target sensory nerve branches, and the cryoablation cycles are performed. Disposable needle/tip and single-use system components are removed and disposed of, hemostasis confirmed, and the patient is observed for recovery and immediate complications before discharge with post-procedure instructions for wound care and activity modification.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
22 | Increased procedural services | Use when the cryoablation required substantially greater resources or work than typical (document rationale). |
23 |